Effect of Rifampin on the Pharmacokinetics of BAY73-4506
NCT01322438
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms
Interventions
DRUG:
Regorafenib (BAY73-4506) + rifampin
Sponsor
Bayer